Skip to main content

Xencor Inc

corporate_fare Company Profile

Xencor Inc

XNCR·NASDAQ·Life Sciences·CIK 0001326732

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune diseases who have unmet medical needs. The company utilizes its protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action. Xencor advances these candidates into clinical-stage development, conducting Phase 1 and Phase 2 studies for a broad portfolio of programs. The company's protein design approach involves engineering Fc domains, which are parts of antibodies that interact with the immune system and control antibody structure. These engineered Fc domains, which are constant and interchangeable across antibodies, provide specific features such as bispecific structure and extended half-life, serving as scaffolds for XmAb drug candidates. Xencor and its partners develop XmAb antibodies and other biotherapeutic drug candidates with improved properties and functionality. Applications of their protein engineering technologies include multi-specific antibodies that engage two or more targets simultaneously, enhancing antibody performance by increasing immune inhibitory activity, improving cytotoxicity, extending circulating half-life, and stabilizing novel protein structures. Three marketed medicines have been developed using Xencor's XmAb protein engineering technologies. The company's modular approach to protein engineering allows for the design of multiple XmAb drug candidates with distinct and novel mechanisms of action. Xencor's business, research, and clinical efforts are focused on developing and advancing a portfolio of XmAb drug candidates in oncology and autoimmune diseases.

Xencor Inc (NASDAQ:XNCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for XNCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for XNCR spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Xencor 10-Q: Q3 Swings to $39.4M Profit on $116.5M Revenue; $555.7M Cash Funds Operations Into 2029
  • Xencor Swings to $39.4M Profit as Royalties and Milestones Lift Revenue 5x
  • Analyst Calls XmAb819 Profile 'Unprecedented' as Shares Jump 20% to Near 52-Week High
  • Xencor Picks 400 mcg/kg XmAb819 Dose, Targets Phase 3 by End-2027
  • Xencor Locks Phase 3 Dose for XmAb819 After 45.5% Response Rate in Kidney Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$125.58M
Net Income
-$91.92M
Diluted EPS
-$1.24
Op. Cash Flow
-$135.12M
Free Cash Flow
-$138.27M
Operating Income
-$177.5M
Cash & Equivalents
$54.07M
Total Debt
$119.75M
Debt / Equity
0.19×
Net Margin
-73.2%
Shares Outstanding
71.87M sh
Source: 10-K · filed 2026-02-25 · accession 0001326732-26-000015

Short Interest & Short Volume

6.58 days to cover

FINRA reported short interest of 12,896,418 shares in XNCR as of the October 30, 2026 settlement, a 5.1% increase from the prior period — about 6.6 days to cover at its recent average daily volume. On November 20, 2026, 72.7% of XNCR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,896,418 shares as of October 30, 2026
Change vs prior period▲ 5.1%
Days to cover6.58 at avg daily volume of 1,961,041
Daily short volume (FINRA facilities)72.7% of 394,716 shares on November 20, 2026
5-day average short volume68.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with X →
$33.24 -0.06% today
52-week range · as of 2026-11-04 $10.38 – $35.05
Market cap
$2.5B
Volume
1.2M (0.8× avg)
3-mo avg 1.6M
Live data · 2026-11-21 20:41 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XNCR - Latest Insights

XNCR
Nov 04, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $33.24 info
Change: -$2.76 (-8%) info
Market Cap: $2.496B info
XNCR
Nov 04, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $34.98
Real-time Price: $33.24 info
Change: -$1.73 (-5%) info
Market Cap: $2.496B info
XNCR
Oct 26, 2026, 1:00 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $30.18
Real-time Price: $33.24 info
Change: +$3.07 (+10%) info
Market Cap: $2.496B info
XNCR
Oct 26, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.02
Real-time Price: $33.24 info
Change: -$0.7835 (-2%) info
Market Cap: $2.496B info
XNCR
Oct 25, 2026, 4:35 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.55
Real-time Price: $33.24 info
Change: +$7.69 (+30%) info
Market Cap: $2.496B info
XNCR
Aug 05, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.84
Real-time Price: $33.24 info
Change: +$13.40 (+68%) info
Market Cap: $2.496B info
XNCR
Jul 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.78
Real-time Price: $33.24 info
Change: +$13.46 (+68%) info
Market Cap: $2.496B info
XNCR
Jun 18, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.64
Real-time Price: $33.24 info
Change: +$20.60 (+163%) info
Market Cap: $2.496B info
XNCR
May 06, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $12.50
Real-time Price: $33.24 info
Change: +$20.74 (+166%) info
Market Cap: $2.496B info
XNCR
May 06, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $12.75
Real-time Price: $33.24 info
Change: +$20.49 (+161%) info
Market Cap: $2.496B info
XNCR
May 06, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.01
Real-time Price: $33.24 info
Change: +$20.23 (+155%) info
Market Cap: $2.496B info
XNCR
May 05, 2026, 8:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.42
Real-time Price: $33.24 info
Change: +$19.82 (+148%) info
Market Cap: $2.496B info
XNCR
Apr 27, 2026, 4:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $13.10
Real-time Price: $33.24 info
Change: +$20.14 (+154%) info
Market Cap: $2.496B info
XNCR
Apr 27, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $13.10
Real-time Price: $33.24 info
Change: +$20.14 (+154%) info
Market Cap: $2.496B info
XNCR
Apr 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.10
Real-time Price: $33.24 info
Change: +$20.14 (+154%) info
Market Cap: $2.496B info
XNCR
Mar 09, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.87
Real-time Price: $33.24 info
Change: +$21.37 (+180%) info
Market Cap: $2.496B info
XNCR
Mar 04, 2026, 4:03 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $12.67
Real-time Price: $33.24 info
Change: +$20.57 (+162%) info
Market Cap: $2.496B info
XNCR
Mar 04, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.74
Real-time Price: $33.24 info
Change: +$20.50 (+161%) info
Market Cap: $2.496B info
XNCR
Feb 25, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $11.98
Real-time Price: $33.24 info
Change: +$21.26 (+177%) info
Market Cap: $2.496B info
XNCR
Feb 25, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.98
Real-time Price: $33.24 info
Change: +$21.26 (+177%) info
Market Cap: $2.496B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets